Literature DB >> 23665322

Gambogic acid induces EGFR degradation and Akt/mTORC1 inhibition through AMPK dependent-LRIG1 upregulation in cultured U87 glioma cells.

Xin-yao He1, Xian-jin Liu, Xiao Chen, Liu-guan Bian, Wei-guo Zhao, Jian-kang Shen, Qing-fang Sun.   

Abstract

Glioblastoma multiforme (GBM) is the most common malignant tumor in adults' central nervous system (CNS). The development of novel anti-cancer agents for GBM is urgent. In the current study, we found that gambogic acid induced growth inhibition and apoptosis in cultured U87 glioma cells, which was associated with Akt/mTORC1 (mTOR complex 1) signaling in-activation. To restore Akt activation by introducing a constitutively active (CA) Akt attenuated gambogic acid-induced cytotoxicity against U87 cells. For mechanism study, we found that gambogic acid induced LRIG1 (leucine-rich repeat and Ig-like domain-containing-1) upregulation, which was responsible for EGFR (epidermal growth factor receptor) degradation and its downstream Akt/mTORC1 inhibition. Further, we provided evidence to support that AMPK (AMP-activated protein kinase) activation mediated gambogic acid-induced LRIG1 upregulation, U87 cell apoptosis and growth inhibition, while AMPK inhibition by shRNA or compound C reduced gambogic acid-induced EGFR/Akt inhibition and cytotoxicity in U87 cells. We here proposed novel signaling mechanism mediating gambogic acid-induced cytotoxic effects in glioma cells.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23665322     DOI: 10.1016/j.bbrc.2013.04.099

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  17 in total

1.  MicroRNA-19a promotes glioma cell growth by repressing LRIG1.

Authors:  Ling-Min Shao; Ji-An Yang; Yue-Fei Wang; Peng Wu; Ji-Qiang Li; Qian-Xue Chen
Journal:  Int J Clin Exp Med       Date:  2014-12-15

Review 2.  EGFR-dependent mechanisms in glioblastoma: towards a better therapeutic strategy.

Authors:  Cristina Zahonero; Pilar Sánchez-Gómez
Journal:  Cell Mol Life Sci       Date:  2014-03-27       Impact factor: 9.261

3.  Potential Application of Gambogic Acid for Retarding Renal Cyst Progression in Polycystic Kidney Disease.

Authors:  Nutchanard Khunpatee; Kanit Bhukhai; Varanuj Chatsudthipong; Chaowalit Yuajit
Journal:  Molecules       Date:  2022-06-15       Impact factor: 4.927

Review 4.  Recent research on bioactive xanthones from natural medicine: Garcinia hanburyi.

Authors:  Buyun Jia; Shanshan Li; Xuerui Hu; Guangyu Zhu; Weidong Chen
Journal:  AAPS PharmSciTech       Date:  2015-07-08       Impact factor: 3.246

5.  The up-regulation of LRIG1 expression inhibits the proliferation, apoptosis and invasion of glioma cells.

Authors:  Zhiyong Zhang; Yuanyuan Wang; Xianxing Wang; Hongguang Zhang; Shuai Wang
Journal:  Am J Transl Res       Date:  2022-02-15       Impact factor: 4.060

Review 6.  LRIG and cancer prognosis.

Authors:  David Lindquist; Samuel Kvarnbrink; Roger Henriksson; Håkan Hedman
Journal:  Acta Oncol       Date:  2014-09-02       Impact factor: 4.089

7.  GSK621 Targets Glioma Cells via Activating AMP-Activated Protein Kinase Signalings.

Authors:  Hong Jiang; Wei Liu; Shi-Kun Zhan; Yi-Xin Pan; Liu-Guan Bian; Bomin Sun; Qing-Fang Sun; Si-Jian Pan
Journal:  PLoS One       Date:  2016-08-17       Impact factor: 3.240

8.  Antitumor activity of gambogic acid on NCI-H1993 xenografts via MET signaling pathway downregulation.

Authors:  Donglei Li; Huiwei Yang; Runpu Li; Yanli Wang; Weijun Wang; Dongjie Li; Shaolin Ma; Xuyu Zhang
Journal:  Oncol Lett       Date:  2015-09-17       Impact factor: 2.967

Review 9.  Synergistic Anticancer Activities of Natural Substances in Human Hepatocellular Carcinoma.

Authors:  Akiko Kojima-Yuasa; Xuedan Huang; Isao Matsui-Yuasa
Journal:  Diseases       Date:  2015-10-22

10.  Gab3 overexpression in human glioma mediates Akt activation and tumor cell proliferation.

Authors:  Pifeng Jia; Feng Li; Weiting Gu; Weifeng Zhang; Yu Cai
Journal:  PLoS One       Date:  2017-03-14       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.